If youâve ever taken an introductory cultural anthropology class, you might recall reading a paper on âBody Ritual among the Nacirema.â Written in 1956, itâs an account of an anthropologist who visits a tribe and observes all kinds of weird behavior â like medicine men who jab coated needles into the flesh of the natives. Some of these natives actually poke themselves with needles, multiple times a day, an act that draws blood which they then use to perform some strange ritual with. Long story short, afterÂ students read this paper, theyâre then asked what they think of the Nacirema, to which most usually respond âwhat a bunch of savages.â Then the punchline comes out. Nacirema is simple the word âAmericanâ spelled backwards. The paper is actually describing modern-day Americans, and even though stabbing yourself with a needle four times a day sounds extremely primitive, itâs what millions of diabetics do every day.
We sat down to talk withÂ a veteran medical professional who has spent the majority of his 30-year careerÂ in anÂ Intensive Care Unit (ICU)Â watching patients file in, many suffering through problems relating to improper blood sugar management. Given their condition, diabetics are treated differently, and it creates problems when medical staff are unaware if someone is a diabetic or not. HeÂ talked about how sometimes a test for blood sugar turns out to be the answer to the patientâs problem, yet this can get easily overlooked. Some patients â think about your teenage kids â choose not to be compliant and consequently end up in ICU so often that theyâre sometimes referred to by medical staff as âfrequent flyers.â Thereâs an immediate need for a technology solution that can monitor glucose and simultaneously administer it as needed. In other words, we need an artificial pancreas for diabetics.
If we can build a medical device with an 11-year battery that helps you manage sleep apnea with a remote, then why canât we develop a device that solves diabetes once and for all? What we need is a closed-loop automatic insulin delivery systemÂ that wouldÂ perform the functions of a pancreas by monitoring glucose and administering it. Letâs talk about glucose monitoring.
We recently wrote a piece on When Will There Be a Cure for Diabetes? in which we talked about companies that are developing therapies for diabetes. Letâs assume for now that the problem isnât going away anytime soon. In order to make life easier for theÂ 450 million diabetics living around the world, we need a system that monitors glucose and administers it as needed such that the patient can live a worry-free life without having to prick their fingers all day like those superstitious Nacirema do. The use of technology to monitor blood sugar levels is hardly innovative. itâs called Continuous Glucose Monitoring (CGM), and an $11 billion company called Dexcom (DXCM) has built an entire business around the idea. A CGM solution involves placing a sensor on or in a patientâs body that then connects to a transmitter which continuously sends regular intervals of glucose readings to a receiver or compatible smart device via Bluetooth technology.
While we donât need to worry about finger sticking anymore with the latest version of this FDA-approved device, we still need to worry about administering insulin as needed. If we can combine CGM with an insulin dispensing system, then weâre just about there. Letâs talk about insulin dispensers and Type I diabetics.
Type 2Â diabetes is a condition where the body produces some insulin but not enough, and accounts for around 90% of all diabetes cases. TypeÂ 1 diabetes is more difficult to manage because the body produces no insulin at all. ManyÂ type 1 diabetics need to worry about administering two types of insulin: basal and bolus. An article from Verywell Health describes the difference between these two types as follows.
Todayâs insulin pumps serve to manage the basal insulin requirement by administering a steady amount of insulin over time, or the bolus insulin based on a patientâs command. About four years ago, we wrote about a company called Cellnovo that was developing a system that would continuously monitors glucose levels and administers insulin when needed as opposed to a steady stream. Just last month, Cellnovo went into bankruptcy proceedings. One reason for that may be the competition.
While there may be any number of companies working on insulin delivery systems, weâre going to focus on a $117 billion medical device company,Â Medtronic (MDT), thatâs a giantÂ in theÂ insulin pump market with a forecasted 2019 share of 63.1%. Weâve held shares of Medtronic for a long time as part of our Dividend Growth Investing (DGI) strategy that focuses on investing in a diversified portfolio of stocks that have a track record of not only paying but increasing dividends over time. Medtronic is one of those companies, having increased their dividend forÂ 41 years in a row now.
Dividend investors might balk at Medtronicâs present yield of 2.20% (about the same return you can get from a savings account these days), but theyâre not considering how fast that dividend has been growing. In the past 10 years, Medtronicâs dividend has increased 11.9% on average every year.Â At that rate of growth, aÂ 2.20% yield would increase to 6.77% in just ten yearsâ time. That sort of consistent growth comes from a well-managed company with a portfolio of high-growth products and a roadmap to bring more such products to market. Thatâs exactly what Medtronic is planning for their âdiabetes group.â
While Medtronicâs diabetes group accounts for less than 10% of total revenues, itâs a high-growth market where Medtronic expects the âartificial pancreasâ to be a standard of care.Â Last summer, the Medtronic diabetes group gave a presentation about all the advancements they expect to make with details about sub-segments and the portion of theÂ market they expect to capture for each. That starts with the MiniMed 670G.
In 2016, the FDA approved the worldâs firstÂ Hybrid Closed Loop (HCL) insulin delivery system, Medtronicâs MiniMed 670G System, which is intended to automatically monitor blood sugar and adjust basal insulin doses in people with type 1 diabetes.Â Hereâs a look at the slide from Medtronic which shows the evolution of the system going forward as more functionality gets added.
There are a few bits of terminology that need explaining here. The term âclosed loopâ refers to the ability of the sensor to communicate with the pump. Thatâs significant because it allows for insulin to be monitored and administered simultaneously. The second term is âhybridâ which refers to the fact that the patient will still need to administer bolus injections before meals. The process becomes easier with a hybrid system since it lets the patient know what dosage they ought to use.Â Based on the above slide,Â we can expect a closed loop automatic insulin delivery system that handles bolus injections and basal injections by some time in the early 2020s. While thatâs not very specific, it makes sense to start using the present-day device which makes diabetes easier to manage â at least according to the 93% of patients who reported being satisfied with the device. But patient satisfaction isnât enough. Insurance companies want to see value being added, and one way to show that is through something called âTime In Range.â
One term that all diabetics will be familiar with is Time In Range (TIR)Â whichÂ is the percentage of time a patient is within the glycemic range of 70 to 180 mg/dL. Evidence suggests that time in range is inversely correlated to risk of developing vascular complications in patients with diabetes,â according to a paper on the topic. In other words, the higher the TIR, the better.
According to an article by Diatribe, for a population of Type 1 diabetic patients, the âaverageÂ time-in-range is likely 40%-50%.â The article goes on to say that âa goal of 70% time-in-range, or even 60%, is likely unrealistic without drastic changes in their diabetes management approach.âÂ Using theÂ Medtronic 670G brings that number up to 71%.Â In 2020, Medtronic plans to release the 780G which bringsÂ TIR up to around 80%. Just a few months ago, they received Breakthrough Device designation for the 890G which promises to bring that number above 85%. Theyâre also using artificial intelligence to improve the accuracy of their devices as well.
Every diabetic patient is different, and thereâs no one-size-fits-all treatment. Thatâs why a âpersonalized medicineâ approach is needed, and thatâs exactly where machine learning algorithms come into play. As you can imagine, constant glucose monitoring produces huge amounts of big data that can then be munched on by hungry AI algorithms to provide predictive analytics that increase TIR according to each patientâs unique anatomyÂ and lifestyle. Medtronicâs app â Sugar IQ â is already doing this with a little help from IBMâs Watson.
Late last year, Medtronic acquired an Israeli firm calledÂ Neutrino HealthÂ which is building the worldâs largest nutritional database and had partnered with Medtronic to âimprove diabetes management through understanding a patientâs Glucose FoodPrint.â Nutrino is doing some pretty cool stuff, like using Natural Language Processing (NLP) to read through more than 10,000 papersÂ to understand nutritional recommendations. Thatâs just one data input stream, with others including things like genetics, social media info, blood tests, food consumption, and the list goes on.
Looks like that partnership with Medtronic worked out pretty well for Nutrino.
When it comes to which company will be first-to-market with an artificial pancreas that handles both bolus and basal injections, itâs not a stretch to think that Medtronic would be the one. They have a roadmap in place, and theyâve managed to secure FDA approval for their first-generation device which already has more than 135,000 people using it. This device serves to simplify the process of managingÂ the diabetic condition, and further advances will only make that process simpler. In a decadeâs time, itâs not hard to imagine a world whereÂ the Nacirima have vanished entirely, replaced by technology that makes their antiquated finger-pricking methods go the way of the dodo.
Are you paying too much in transaction fees to your broker? Check out a brokerage firm called Zacks Trade that’s offering $1Â trades for U.S. stocks and options until 2020.Â After that, you’ll pay just $3 a trade or a penny a share, whichever is greater.Â It’s one of the cheapest brokers out there and you can also trade stocks on foreign stock exchanges. Â Trade US stocks and options for as low as $1 per order until 2020.